Stock listing

NASDAQ:BCYC Bicycle Therapeutics PLC Stock

Follow Bicycle Therapeutics PLC into a list and get an email when it puts out news.

Share price · NASDAQ:BCYC

$2.90 USD -0.21 (-6.8%)

Close on Nov 20, 2026

Past year -53.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.85 – $3.00 USDNov 20, 2026
Volume
1.02M sharesNov 20, 2026
Market cap
$146.1M USDAt the close on Nov 20, 2026 · price × 50.37M shares outstanding
52-week range
$2.85 – $7.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.64M USDMedian day 379,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Bicycle Therapeutics PLC logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BCYC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.90-0.21-6.8%$2.99$3.00$2.851,023,517
$3.11-0.09-2.8%$3.20$3.27$3.095567,648
$3.20+0.02+0.6%$3.18$3.22$3.12445,392
$3.18-0.19-5.6%$3.33$3.36$3.07676,101
$3.37-0.08-2.3%$3.45$3.50$3.26604,366
$3.45-0.24-6.5%$3.65$3.655$3.43630,100
$3.690.000.0%$3.73$3.75$3.665171,799
$3.69-0.08-2.1%$3.77$3.78$3.65234,733
$3.77+0.16+4.4%$3.69$3.84$3.57590,237
$3.61+0.13+3.7%$3.50$3.685$3.49235,641
$3.48-0.24-6.5%$3.69$3.69$3.465499,184
$3.72+0.05+1.4%$3.75$3.80$3.65215,100
$3.67+0.05+1.4%$3.61$3.71$3.6181,485
$3.62-0.04-1.1%$3.69$3.76$3.58348,214
$3.66-0.16-4.2%$3.75$3.80$3.60347,481
$3.82-0.06-1.5%$3.92$4.13$3.71598,172
$3.88+0.10+2.6%$3.76$3.89$3.71436,241
$3.78+0.13+3.6%$3.66$3.84$3.61486,229
$3.65+0.10+2.8%$3.66$3.69$3.53525,704
$3.55-0.09-2.5%$3.64$3.64$3.415346,800
$3.64+0.07+2.0%$3.56$3.64$3.525276,200
$3.57-0.03-0.8%$3.62$3.797$3.56406,400
$3.60+0.065+1.8%$3.53$3.71$3.52488,100
$3.535+0.075+2.2%$3.45$3.64$3.41692,100
$3.46-0.14-3.9%$3.58$3.60$3.42565,600
$3.60+0.09+2.6%$3.51$3.64$3.50411,500
$3.51-0.12-3.3%$3.63$3.755$3.50438,300
$3.63-0.17-4.5%$3.81$3.88$3.63457,200
$3.80-0.09-2.3%$3.89$3.91$3.785233,300
$3.89+0.08+2.1%$3.81$3.92$3.775300,600
$3.81+0.08+2.1%$3.71$3.81$3.62337,700
$3.73-0.06-1.6%$3.75$3.805$3.68472,600
$3.79-0.22-5.5%$4.02$4.025$3.735620,700
$4.01+0.63+18.6%$3.62$4.039$3.611,844,000
$3.38-0.18-5.1%$3.65$3.695$3.33728,700
$3.56-0.12-3.3%$3.67$3.74$3.55379,900
$3.68+0.03+0.8%$3.69$3.77$3.66295,100
$3.65-0.06-1.6%$3.72$3.77$3.635206,200
$3.71+0.025+0.7%$3.69$3.81$3.578442,500
$3.685-0.045-1.2%$3.73$3.73$3.65238,900
$3.73+0.13+3.6%$3.66$3.95$3.66820,000
$3.60-0.13-3.5%$3.72$3.72$3.57374,200
$3.73+0.10+2.8%$3.67$3.83$3.65554,700
$3.63-0.02-0.5%$3.70$3.77$3.63266,500
$3.65-0.03-0.8%$3.69$3.70$3.63240,400
$3.68+0.04+1.1%$3.73$3.79$3.67185,100
$3.64-0.03-0.8%$3.68$3.725$3.605599,900
$3.67-0.22-5.7%$3.88$3.895$3.65544,100
$3.89+0.03+0.8%$3.90$3.95$3.83209,400
$3.86+0.03+0.8%$3.87$3.955$3.83621,200
$3.83-0.175-4.4%$3.99$3.99$3.811,942,100
$4.005-0.175-4.2%$4.17$4.17$3.985399,600
$4.18-0.12-2.8%$4.28$4.28$4.17262,900
$4.30+0.06+1.4%$4.20$4.305$4.145157,500
$4.24-0.06-1.4%$4.32$4.36$4.20268,100
$4.30+0.20+4.9%$4.10$4.39$4.10317,600
$4.10-0.03-0.7%$4.12$4.272$4.075316,700
$4.13-0.07-1.7%$4.21$4.32$4.10235,600
$4.20-0.13-3.0%$4.32$4.44$4.19154,700
$4.33-0.025-0.6%$4.36$4.45$4.28104,900
$4.355-0.035-0.8%$4.41$4.41$4.28166,100
$4.39+0.06+1.4%$4.38$4.48$4.35209,895
$4.33-0.04-0.9%$4.33$4.39$4.27144,091
$4.37+0.13+3.1%$4.29$4.51$4.252480,700
$4.24+0.10+2.4%$4.11$4.27$4.035374,100
Ticker
NASDAQ:BCYC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Bicycle Therapeutics PLC news

Bicycle Therapeutics PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 1 in all · newest Oct 29, 2026 · oldest 2026
Decks
4 decks · latest October 2022

Valuation

EV/sales −3.9× against a median of 17.8×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$323.8M USD
P/E
Loss
EV/sales
−3.9×
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
Not reported
Operating margin
−189.4%
Net margin
−169.8%
Debt to equity
0.0×
Beta vs S&P 500
1.59

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.1Mn/an/an/a3.7×n/a0.6×n/a
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.39Mn/a29.9×n/a1.4×n/a0.3×n/a
Median of the othersUS$146.7MUS$86.03M8.4×17.8×5.2×1.7×−210.7%0.1×1.41

Forecasts

4 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
9.17 USD · Analysts' mean
EPS, year to Dec 2026
-2.26 · 8 analysts
Revenue, year to Dec 2026
38.15M · 9 analysts

Team and board

DirectorRole
Hervé HoppenotChairperson
Jose-Carlos Gutierrez-RamosChairperson
Stephen SandsChairperson
Alessandro Riva
Felix J. Baker
Roger Dansey

Events

QuarterResultsShare move
Q3 2026Oct 29, 2026 · Before open−1.6%
Q2 2026Jul 30, 2026 · Before open+3.9%
Q1 2026Apr 30, 2026 · Before open−0.2%
Q4 2025Mar 3, 2026−1.8%
Q3 2025Oct 30, 2025 · Before open+7.1%
Q2 2025Aug 8, 2025 · Before open+2.5%
Q1 2025May 1, 2025 · Before open+6.1%
Q4 2024Feb 18, 2025 · Before open−3.1%
Q3 2024Oct 31, 2024 · Before open−2.4%
Q2 2024Aug 6, 2024 · Before open+7.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · Before open+2.0%
Q4 2023Feb 20, 2024 · Before open+0.8%
Q3 2023Nov 2, 2023 · Before open−2.9%
Q2 2023Aug 3, 2023 · Before open−0.1%
Q1 2023May 4, 2023 · Before open−4.3%
Q4 2022Feb 28, 2023 · Before open−2.0%
Q3 2022Nov 3, 2022 · Before open−0.5%
Q2 2022Aug 4, 2022 · Before open+11.1%
Q1 2022May 5, 2022 · Before open−5.6%
Q4 2021Mar 1, 2022 · Before open−0.4%

Open Events

Decks

DeckKindSlidesDate
ESCMID 2022Conference18 slidesOctober 2022
Technical Presentation (April 2022)Technical23 slidesApr 12, 2022
Corporate Update (October 2021)Corporate update30 slidesOct 7, 2021
AACR Annual Meeting 2019Conference11 slides2019

Open Decks

IPO

Priced at US$14.00 an ADS on May 22, 2019.

Price
US$14.00 an ADS
ADSs offered
4,333,333 American depositary shares
Offering size
US$60.7 million
Underwriters' option
Up to 650,000 more ADSs
Listing
BCYC on the Nasdaq Global Select Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Piper Jaffray, Canaccord Genuity · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceDec 21, 2018
Filed publiclyApr 26, 2019
Amended twiceNewest May 15, 2019
Shares registered with an exchangeMay 20, 2019
Declared effective by the SECMay 22, 2019
Final prospectus, with the priceMay 23, 2019

Open IPO · From the cover of the final prospectus (424B4) filed May 23, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue72.6M35.3M27.0M14.5M11.7M10.4M13.8M7.14M2.06M
Research and development240.3M173.0M156.5M81.6M44.9M33.1M25.5M20.8M11.9M
Operating income-247.1M-209.9M-189.9M-116.7M-65.6M-52.0M-26.3M-21.7M-16.2M
Depreciation and amortization6.42M7.17M6.55M3.69M1.41M1.28M960.0K712.0K332.0K
EBITDA-240.6M-202.7M-183.4M-113.0M-64.2M-50.7M-25.3M-21.0M-15.9M
Interest expense206.0K1.73M3.26M3.34M2.98M457.0K
Income before tax-218.8M-173.8M-179.2M-114.2M-68.5M-51.7M-30.9M-22.2M-16.3M
Income tax152.0K-4.76M1.46M-1.52M-1.66M-724.0K-254.0K-396.0K-23.0K
Net income-219.0M-169.0M-180.7M-112.7M-66.8M-51.0M-30.6M-21.8M-16.3M
Earnings per share, basic-3.16-2.90-5.08-3.80-2.67-2.66-2.77-49.78-48.81
Earnings per share, diluted-3.16-2.90-5.08-3.80-2.67-2.66-2.77-49.78-48.81

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents628.1M879.5M526.4M339.2M438.7M00067.7M
Receivables0002.04M1.00M5.46M201.0K5.02M
Current assets682.9M928.6M561.9M369.4M458.6M155.7M104.1M76.8M
Property, plant and equipment6.02M9.52M14.5M19.1M3.12M2.32M2.29M1.82M
Total assets717.6M956.9M595.3M410.6M479.8M161.2M110.2M81.6M
Accounts payable9.67M15.8M13.1M6.47M2.72M1.36M1.95M1.89M
Current liabilities57.0M67.2M69.5M53.3M36.2M23.1M8.82M8.93M
Long-term debt30.7M30.3M29.9M14.5M
Total debt30.7M30.3M29.9M14.5M
Total liabilities107.6M163.8M224.4M139.8M133.5M65.7M17.0M29.3M
Shareholders' equity610.0M793.1M370.9M270.8M346.3M95.5M93.2M-69.8M-47.2M
Shares outstanding69.4M69.1M42.4M29.9M29.6M21.1M18.0M814.7K23.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-249.7M-164.7M-60.6M-86.1M-14.8M-17.8M-28.6M-26.1M-1.42M
Capital spending-2.35M-1.24M-2.93M-19.0M-2.03M-1.20M-1.55M-1.19M-1.11M
Free cash flow-252.0M-166.0M-63.6M-105.1M-16.8M-19.0M-30.2M-27.3M-2.53M
Cash from investing-2.35M-1.24M-2.93M-19.0M-2.03M-1.20M-1.55M-1.19M-1.11M
Cash from financing-131.0K519.8M250.0M6.69M320.7M62.8M58.4M25.4M57.9M
Change in cash-251.4M353.1M187.8M-99.5M302.7M43.9M28.7M-4.28M58.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
4/A · Change in ownership, amendedOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3/A · Initial statement of ownership, amendedOct 6, 2026Insider tradeSEC
144 · Notice of proposed saleOct 2, 2026Other filingsSEC
8-K · Current reportAug 20, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
8-K · Current reportMay 21, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 4, 2026Big-stake noticeSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026ResultsSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 3, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
3 · Initial statement of ownershipMar 25, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 17, 2026Offer documentSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
8-K · Current reportMar 17, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 3, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 3, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 3, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
8-K · Current reportFeb 3, 2026Management or board changeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
S-8 · Registration statement for employee plansOct 30, 2025Offer documentSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
4 · Change in ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
8-K · Current reportSep 8, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveAug 15, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2025Insider tradeSEC
424B3 · ProspectusAug 14, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
CORRESP · Letter to the SECAug 12, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 12, 2025Other filingsSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
8-K · Current reportApr 29, 2025Current reportSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2025Insider tradeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2025Insider tradeSEC
8-K · Current reportMar 27, 2025Management or board changeSEC
8-K · Current reportMar 14, 2025Current reportSEC
S-8 · Registration statement for employee plansFeb 25, 2025Offer documentSEC
10-K · Annual reportFeb 25, 2025Annual reportSEC
8-K · Current reportFeb 25, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeDec 20, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 19, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedDec 17, 2024Big-stake noticeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
8-K · Current reportDec 13, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
10-Q · Quarterly reportOct 31, 2024Quarterly reportSEC

This page holds 200 of 661 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Bicycle Therapeutics PLC’s releases

Common shares
50,373,281
Fully diluted
50,373,281

Fully diluted

LineShares
Common shares50,373,281

Share count over time

CountShares
Nov 22, 202650,373,281

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Baker Bros. Advisors LP10.9M21.6%US$40.1MSep 30, 2026
Armistice Capital, LLC3.47M6.9%US$12.8MSep 30, 2026
Fcpm III Services B.V.3.47M6.9%US$12.8MSep 30, 2026
Long Focus Capital Management, LLC3.31M6.6%US$12.2MSep 30, 2026
Acadian Asset Management LLC1.99M4.0%US$7.31MSep 30, 2026
GSK plc1.53M3.0%US$5.63MSep 30, 2026
Renaissance Technologies1.51M3.0%US$5.55MSep 30, 2026
Two Sigma1.12M2.2%US$4.12MSep 30, 2026
Qube Research & Technologies Ltd840K1.7%US$3.09MSep 30, 2026
Marshall Wace, LLP836K1.7%US$3.08MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Morgan Stanley641K1.3%US$2.36MSep 30, 2026
Schroders616K1.2%US$2.25MSep 30, 2026
Millennium563K1.1%US$2.07MSep 30, 2026
Peapod Lane Capital LLC502K1.00%US$1.85MSep 30, 2026
Diadema Partners LP399K0.79%US$1.47MSep 30, 2026
Citadel370K0.73%US$1.36MSep 30, 2026
BlackRock330K0.66%US$1.21MSep 30, 2026
Moore Capital Management, LP275K0.55%US$1.01MSep 30, 2026
Rangeley Capital, LLC235K0.47%US$865KSep 30, 2026
Nano Cap New Millennium Growth Fund L P193K0.38%US$708KSep 30, 2026
Eversept Partners, LP190K0.38%US$699KSep 30, 2026
Palo Alto Investors LP188K0.37%US$693KSep 30, 2026
Flax Pond Capital, LLC183K0.36%US$674KSep 30, 2026
Birchview Capital, LP176K0.35%US$649KSep 30, 2026
Pinnacle Associates LTD161K0.32%US$591KSep 30, 2026
Susquehanna121K0.24%US$447KSep 30, 2026
Point72 Asset Management, L.P.119K0.24%US$439KSep 30, 2026
Persistent Asset Partners Ltd101K0.20%US$372KSep 30, 2026
Goldman Sachs98,5710.20%US$363KSep 30, 2026
Jump Financial, LLC82,8710.16%US$305KSep 30, 2026
Virtus Investment Advisers, LLC78,3540.16%US$288KSep 30, 2026
Alps Advisors Inc66,5010.13%US$245KSep 30, 2026
Jane Street65,5750.13%US$241KSep 30, 2026
State of Tennessee, Department of Treasury61,1530.12%US$225KSep 30, 2026
Sei Investments Co52,7840.10%US$194KSep 30, 2026
Gsa Capital Partners LLP47,9680.10%US$177KSep 30, 2026
Simplex Trading, LLC46,9230.09%US$173KSep 30, 2026
Axq Capital, LP38,6450.08%US$142KSep 30, 2026
Tocqueville Asset Management L.P.38,5000.08%US$142KSep 30, 2026
State Street37,2250.07%US$137KSep 30, 2026
Hrt Financial LP32,5350.06%US$119KSep 30, 2026
Forefront Analytics, LLC32,3570.06%US$119KSep 30, 2026
Invesco32,3090.06%US$119KSep 30, 2026
XTX Topco Ltd31,5590.06%US$116KSep 30, 2026
D. E. Shaw & Co., Inc.30,9570.06%US$114KSep 30, 2026
R Squared Ltd26,6570.05%US$98,098Sep 30, 2026
Stifel Financial Corp23,3490.05%US$85,924Sep 30, 2026
Vontobel Holding Ltd.23,0000.05%US$84,640Sep 30, 2026
49 Wealth Management, LLC22,7770.05%US$83,819Sep 30, 2026
Pinnacle Wealth Management Advisory Group, LLC20,9850.04%US$77,225Sep 30, 2026

This page holds 50 of 88 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC6.85%3.47MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Pierre Legault
Other companies: Syndax Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2017); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Mar 26, 2018 · Past); NPS Pharmaceuticals Inc (Director · Nov 3, 2014 – Feb 21, 2015 · Past); NephroGenex Inc (Chief Executive Officer, Director · Feb 10, 2014 – Nov 10, 2015 · Past); Tobira Therapeutics Inc (Director · Nov 18, 2013 – Nov 1, 2016 · Past); Forest Laboratories Inc (Director · Aug 15, 2013 – Jul 1, 2014 · Past)
Director · May 22, 2019 – Jan 2, 2025 · Past
Richard Kender
Other companies: Longeveron Inc. (Director · Since at least May 10, 2024); Seres Therapeutics, Inc. (See Remarks, Director · Since at least Apr 4, 2024); Omega Therapeutics Inc (Director · Jun 20, 2024 – Jun 20, 2024 · Past)
Director · Jan 2, 2024 – Jan 2, 2025 · Past
Alessandro Riva
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 12, 2025)
Director · Since at least Jan 2, 2026
Carolyn Ng
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Bicara Therapeutics Inc. (Director · Sep 12, 2024 – Sep 12, 2024 · Past)
Director · May 22, 2019 – May 28, 2019 · Past
Hervé Hoppenot
Other companies: Maze Therapeutics, Inc. (Director · Since at least Oct 6, 2025); Incyte Corporation (Director · Since at least Nov 16, 2020)
Director · Since at least Sep 8, 2025
Lee Kalowski
Other companies: Q32 Bio Inc. (PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024); Eledon Pharmaceuticals, Inc. (Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past)
President and CFO · May 22, 2019 – Apr 3, 2023 · Past
Felix J. Baker
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026)
Director · Since at least Nov 5, 2026
Jose-Carlos Gutierrez-Ramos
Other companies: Danaher Corporation (Senior Vice President, Chief Science Officer · Since at least Feb 2, 2026)
Chairperson · Since at least Jan 2, 2026
Santiago Arroyo
Other companies: Fulcrum Therapeutics, Inc. (Chief Medical Officer · Nov 7, 2022 – Nov 7, 2022 · Past)
CHIEF DEVELOPMENT OFFICER · Mar 31, 2023 – Jan 2, 2025 · Past
Janice BourqueDirector · Since at least Jul 18, 2019
All 17 people
PersonSeat
Kevin LeeCHIEF EXECUTIVE OFFICER, Director · Since at least Apr 2, 2025
Michael SkynnerCHIEF SCIENTIFIC OFFICER · Since at least Jan 4, 2021
Nigel CrockettCHIEF BUSINESS OFFICER · Jan 3, 2023 – Jan 2, 2025 · Past
Robert Charles SwantonDirector · Since at least Aug 12, 2025
Roger DanseyDirector · Since at least Nov 5, 2026
Stephen SandsChairperson · Since at least Nov 5, 2026
Travis Alvin ThompsonChief Financial Officer · Since at least Jun 22, 2023

Open People

Log in to ask 6ix AI your own questions about Bicycle Therapeutics PLC.